Company / Revenue
CUMBERLAND PHARMACEUTICALS INC Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$11.7M
FY2025
5-year range
$11.7M / $42.0M
FY2021-FY2025
Trend
-70.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from $600,000 in FY2016 to $42M in FY2023.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of -20.7%.
Declined from $42M to $12M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -31.2%
- 5-Year CAGR
- -20.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -20.7%, indicating a declining trend.
- In FY2025, revenue decreased 70.4% year-over-year.
- Peak revenue was recorded in FY2023.
- Lowest revenue in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.7M | -70.4% |
| FY2024 | $39.6M | -5.9% |
| FY2023 | $42.0M | +16.7% |
| FY2022 | $36.0M | +4.6% |
| FY2021 | $34.4M | -8.2% |
| FY2020 | $37.4M | +8.9% |
| FY2019 | $34.4M | +4.1% |
| FY2018 | $33.0M | +3569.5% |
| FY2017 | $900.0K | +50.0% |
| FY2016 | $600.0K | -25.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026